Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease.

Xun Z, Rivera-Sánchez S, Ayala-Peña S, Lim J, Budworth H, Skoda EM, Robbins PD, Niedernhofer LJ, Wipf P, McMurray CT.

Cell Rep. 2012 Nov 29;2(5):1137-42. doi: 10.1016/j.celrep.2012.10.001. Epub 2012 Nov 1.

2.

Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis.

Ayala-Peña S.

Free Radic Biol Med. 2013 Sep;62:102-10. doi: 10.1016/j.freeradbiomed.2013.04.017. Epub 2013 Apr 18. Review.

3.
4.

Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted anti-oxidants.

Fink MP, Macias CA, Xiao J, Tyurina YY, Jiang J, Belikova N, Delude RL, Greenberger JS, Kagan VE, Wipf P.

Biochem Pharmacol. 2007 Sep 15;74(6):801-9. Epub 2007 May 29. Review.

PMID:
17601494
5.

Exploiting proteomics in the discovery of drugs that target mitochondrial oxidative damage.

Gibson BW.

Sci Aging Knowledge Environ. 2004 Mar 17;2004(11):pe12. Review.

PMID:
15028863
6.

The role of oxidative stress in Huntington's disease: are antioxidants good therapeutic candidates?

Gil-Mohapel J, Brocardo PS, Christie BR.

Curr Drug Targets. 2014 Apr;15(4):454-68. Review.

PMID:
24428525
7.

Structural and functional changes in proteins induced by free radical-mediated oxidative stress and protective action of the antioxidants N-tert-butyl-alpha-phenylnitrone and vitamin E.

Butterfield DA, Koppal T, Howard B, Subramaniam R, Hall N, Hensley K, Yatin S, Allen K, Aksenov M, Aksenova M, Carney J.

Ann N Y Acad Sci. 1998 Nov 20;854:448-62. Review.

PMID:
9928452
8.

Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted antioxidants.

Fink MP, Macias CA, Xiao J, Tyurina YY, Delude RL, Greenberger JS, Kagan VE, Wipf P.

Crit Care Med. 2007 Sep;35(9 Suppl):S461-7. Review.

PMID:
17713394
9.

PGC-1α, mitochondrial dysfunction, and Huntington's disease.

Johri A, Chandra A, Beal MF.

Free Radic Biol Med. 2013 Sep;62:37-46. doi: 10.1016/j.freeradbiomed.2013.04.016. Epub 2013 Apr 19. Review.

10.

Antioxidants in Huntington's disease.

Johri A, Beal MF.

Biochim Biophys Acta. 2012 May;1822(5):664-74. doi: 10.1016/j.bbadis.2011.11.014. Epub 2011 Nov 23. Review.

11.

Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases.

Trushina E, McMurray CT.

Neuroscience. 2007 Apr 14;145(4):1233-48. Epub 2007 Feb 14. Review.

PMID:
17303344
12.

Mitochondria, oxidative stress, and temporal lobe epilepsy.

Waldbaum S, Patel M.

Epilepsy Res. 2010 Jan;88(1):23-45. doi: 10.1016/j.eplepsyres.2009.09.020. Epub 2009 Oct 21. Review.

14.

Effects of tempol and redox-cycling nitroxides in models of oxidative stress.

Wilcox CS.

Pharmacol Ther. 2010 May;126(2):119-45. doi: 10.1016/j.pharmthera.2010.01.003. Epub 2010 Feb 11. Review.

15.

Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases.

Chaturvedi RK, Beal MF.

Mol Cell Neurosci. 2013 Jul;55:101-14. doi: 10.1016/j.mcn.2012.11.011. Epub 2012 Dec 5. Review.

PMID:
23220289
16.

Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.

Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, Butterfield DA.

J Neurol Sci. 2005 Jun 15;233(1-2):145-62. Review.

PMID:
15896810
17.

Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models.

Browne SE.

Ann N Y Acad Sci. 2008 Dec;1147:358-82. doi: 10.1196/annals.1427.018. Review.

PMID:
19076457
18.

Oxidative damage and mutation to mitochondrial DNA and age-dependent decline of mitochondrial respiratory function.

Wei YH, Lu CY, Lee HC, Pang CY, Ma YS.

Ann N Y Acad Sci. 1998 Nov 20;854:155-70. Review.

PMID:
9928427
19.

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Pandi-Perumal SR, BaHammam AS, Brown GM, Spence DW, Bharti VK, Kaur C, Hardeland R, Cardinali DP.

Neurotox Res. 2013 Apr;23(3):267-300. doi: 10.1007/s12640-012-9337-4. Epub 2012 Jun 28. Review.

PMID:
22739839
20.

Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants.

Stack EC, Matson WR, Ferrante RJ.

Ann N Y Acad Sci. 2008 Dec;1147:79-92. doi: 10.1196/annals.1427.008. Review.

PMID:
19076433

Supplemental Content

Support Center